Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Immunogenicity
100%
Influenza
100%
MRNA Vaccine
100%
Mouse Animal Model
100%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
100%
Combined Vaccine
100%
Lung
28%
COVID-19
28%
Survival Rate
14%
Vaccine Candidate
14%
Paediatric Practice
14%
Enzyme-linked Immunosorbent Assay (ELISA)
14%
Vaccination Coverage
14%
Protective Efficacy
14%
Viral Challenge
14%
Multivalent Vaccine
14%
Viral Load
14%
Long Non-coding RNA (LncRNA)
14%
Hemagglutination Inhibition
14%
Single Infection
14%
Efficacy Profile
14%
Seasonal Influenza
14%
Number of Visits
14%
Viable Virus
14%
Vaccination Schedule
14%
H1N1 Influenza Virus
14%
Number of Injections
14%
Mutual Interference
14%
SARS-CoV-2 Antigen
14%
Vaccine Cost
14%
Microfluidic Mixing
14%
Immunotherapy Efficacy
14%
Vaccine Storage
14%
Virus Neutralization Assay
14%
Pregenomic RNA (pgRNA)
14%
Challenge Model
14%
Human Vaccination
14%
Vaccine Monitoring
14%
Pharmacology, Toxicology and Pharmaceutical Science
Immunogenicity
100%
SARS Coronavirus
100%
Influenza
100%
mRNA Vaccine
100%
Messenger RNA
100%
Vaccination
66%
Virus
33%
Antigen
16%
Infection
16%
Immunoassay
16%
Survival Rate
16%
Virus RNA
16%
Enzymes
16%
Influenza A Virus (H1N1)
16%
Seasonal Influenza
16%
Side Effect
16%
Immunology and Microbiology
Immunogenicity
100%
Influenza
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
COVID-19
40%
Lung
40%
Survival Rate
20%
Infectious Disease
20%
Antigen
20%
Viral Load
20%
Influenza A Virus (H1N1)
20%
Immunoassay
20%
Hemagglutination Inhibition
20%
Virus Neutralization
20%
Vaccination Schedule
20%
Virus
20%
Infection
20%
Ribonucleic Acid
20%
Lipid Nanoparticles
20%